

Author's Accepted Manuscript

Predictors of Benzodiazepine Use in a Transdiagnostic Sample of Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder Patients

Luana D. Laurito, Carla P. Loureiro, Rafaela V. Dias, Paula Vigne, Gabriela B. de Menezes, Rafael C. Freire, Ulrich Stangier, Leonardo F. Fontenelle



PII: S0165-1781(17)31267-2
DOI: <https://doi.org/10.1016/j.psychres.2018.02.013>
Reference: PSY11187

To appear in: *Psychiatry Research*

Received date: 9 July 2017
Revised date: 13 January 2018
Accepted date: 2 February 2018

Cite this article as: Luana D. Laurito, Carla P. Loureiro, Rafaela V. Dias, Paula Vigne, Gabriela B. de Menezes, Rafael C. Freire, Ulrich Stangier and Leonardo F. Fontenelle, Predictors of Benzodiazepine Use in a Transdiagnostic Sample of Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder Patients, *Psychiatry Research*, <https://doi.org/10.1016/j.psychres.2018.02.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Predictors of Benzodiazepine Use in a Transdiagnostic Sample of Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder Patients

Luana D. Laurito, Psic.¹, Carla P. Loureiro, Psic., Rafaela V. Dias, Psic.¹, Paula Vigne, M.D., M.Sc.¹, Gabriela B. de Menezes, M.D., Ph.D.¹, Rafael C. Freire; M.D., Ph.D.², Ulrich Stangier, Ph.D.³, Leonardo F. Fontenelle, M.D., Ph.D.^{1,4,5*}

¹ Obsessive, Compulsive, and Anxiety Spectrum Research Program. Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil.

² Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro.

³ Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University of Frankfurt, Varrentrappstr. 40-42, 60486, Frankfurt, Germany.

⁴D'Or Institute for Research and Education, Rio de Janeiro, Brazil.

⁵Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, Australia.

*Correspondence and reprints: Leonardo F. Fontenelle, M.D., Ph.D., Rua Visconde de Pirajá, 547, 617 Ipanema, Rio de Janeiro-RJ, Brazil, CEP: 22410-003. Fax and tel.+ 55-21-2239-4919. lfontenelle@gmail.com

ABSTRACT

We investigated the rates of current and past benzodiazepine (BZD) use in a sample of 102 subjects attending specialized anxiety disorder clinics, including panic disorder (PD; N= 36), social anxiety disorder (SAD; N=28) and obsessive-compulsive disorder (OCD; N=38) patients. Almost 56% of the entire sample was using BZDs at the moment of the assessment, and 74.5% described having used them at some point during their lifetimes. The duration of psychiatric treatment and a lifetime history of PD, but not any other “transdiagnostic” measure of severity (such as the Panic and Agoraphobia Scale, the Social Phobia Inventory, the Dimensional Obsessive-Compulsive Scale, the Anxiety Sensitivity Index-36, and the Beck Inventories) were independent risk factors for current prescription of BZDs. Patients who continued to use BZDs differed from patients who stopped them by being older (both currently and when firstly seen in the clinic), by

Download English Version:

<https://daneshyari.com/en/article/6811619>

Download Persian Version:

<https://daneshyari.com/article/6811619>

[Daneshyari.com](https://daneshyari.com)